232 related articles for article (PubMed ID: 23788687)
1. Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease.
Grasemann C; Schündeln MM; Hövel M; Schweiger B; Bergmann C; Herrmann R; Wieczorek D; Zabel B; Wieland R; Hauffa BP
J Clin Endocrinol Metab; 2013 Aug; 98(8):3121-6. PubMed ID: 23788687
[TBL] [Abstract][Full Text] [Related]
2. Denosumab treatment for juvenile Paget's disease: results from two adult patients with osteoprotegerin deficiency ("Balkan" mutation in the TNFRSF11B gene).
Polyzos SA; Singhellakis PN; Naot D; Adamidou F; Malandrinou FC; Anastasilakis AD; Polymerou V; Kita M
J Clin Endocrinol Metab; 2014 Mar; 99(3):703-7. PubMed ID: 24433001
[TBL] [Abstract][Full Text] [Related]
3. Juvenile paget's disease in an Iranian kindred with vitamin D deficiency and novel homozygous TNFRSF11B mutation.
Saki F; Karamizadeh Z; Nasirabadi S; Mumm S; McAlister WH; Whyte MP
J Bone Miner Res; 2013 Jun; 28(6):1501-8. PubMed ID: 23322328
[TBL] [Abstract][Full Text] [Related]
4. [Denosumab as the potent therapeutic agent against Paget's disease of bone].
Hirao M; Hashimoto J
Clin Calcium; 2011 Aug; 21(8):1231-8. PubMed ID: 21814030
[TBL] [Abstract][Full Text] [Related]
5. Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B "Balkan" mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels.
Whyte MP; Singhellakis PN; Petersen MB; Davies M; Totty WG; Mumm S
J Bone Miner Res; 2007 Jun; 22(6):938-46. PubMed ID: 17352649
[TBL] [Abstract][Full Text] [Related]
6. Rhizomelia and Impaired Linear Growth in a Girl with Juvenile Paget Disease: The Natural History of the Condition.
Höppner J; Steff K; Lobert F; Heyer CM; Hauffa BP; Grasemann C
Horm Res Paediatr; 2021; 94(3-4):151-158. PubMed ID: 34261073
[TBL] [Abstract][Full Text] [Related]
7. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R
Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
[TBL] [Abstract][Full Text] [Related]
8. Juvenile Paget's Disease From Heterozygous Mutation of SP7 Encoding Osterix (Specificity Protein 7, Transcription Factor SP7).
Whyte MP; Campeau PM; McAlister WH; Roodman GD; Kurihara N; Nenninger A; Duan S; Gottesman GS; Bijanki VN; Sedighi H; Veis DJ; Mumm S
Bone; 2020 Aug; 137():115364. PubMed ID: 32298837
[TBL] [Abstract][Full Text] [Related]
9. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
10. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
Body JJ; Facon T; Coleman RE; Lipton A; Geurs F; Fan M; Holloway D; Peterson MC; Bekker PJ
Clin Cancer Res; 2006 Feb; 12(4):1221-8. PubMed ID: 16489077
[TBL] [Abstract][Full Text] [Related]
11. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
12. Paget's disease of the bone after treatment with Denosumab: a case report.
Schwarz P; Rasmussen AQ; Kvist TM; Andersen UB; Jørgensen NR
Bone; 2012 May; 50(5):1023-5. PubMed ID: 22586699
[TBL] [Abstract][Full Text] [Related]
13. Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy.
Cundy T; Wheadon L; King A
J Bone Miner Res; 2004 May; 19(5):703-11. PubMed ID: 15068492
[TBL] [Abstract][Full Text] [Related]
14. Juvenile Paget's disease with heterozygous duplication within TNFRSF11A encoding RANK.
Whyte MP; Tau C; McAlister WH; Zhang X; Novack DV; Preliasco V; Santini-Araujo E; Mumm S
Bone; 2014 Nov; 68():153-61. PubMed ID: 25063546
[TBL] [Abstract][Full Text] [Related]
15. Denosumab in postmenopausal women with low bone mineral density.
McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Paget's Disease of Bone with Denosumab: Case Report and Literature Review.
Reid IR; Sharma S; Kalluru R; Eagleton C
Calcif Tissue Int; 2016 Sep; 99(3):322-5. PubMed ID: 27193832
[TBL] [Abstract][Full Text] [Related]
17. [Paget's disease of bone: new therapeutic strategies].
D'Amore M; Lisi S; Sisto M; De Marino AV
Recenti Prog Med; 2013 Mar; 104(3):89-92. PubMed ID: 23548950
[TBL] [Abstract][Full Text] [Related]
18. [Cytokines in bone diseases. Osteoprotegerin and juvenile Paget's disease].
Hosogane N; Miyamoto T
Clin Calcium; 2010 Oct; 20(10):1540-4. PubMed ID: 20890037
[TBL] [Abstract][Full Text] [Related]
19. Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.
Cremers S; Garnero P
Drugs; 2006; 66(16):2031-58. PubMed ID: 17112299
[TBL] [Abstract][Full Text] [Related]
20. Denosumab for the treatment of bone metastases in advanced breast cancer.
Casas A; Llombart A; Martín M
Breast; 2013 Oct; 22(5):585-92. PubMed ID: 23759273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
